Celgene: Still A Great Pipeline, Despite A Setback

Celgene (CELG) is a very interesting biotechnology company with a truly long-term focus and tolerance for risk. While some large pharma names acquire promising companies which are on the verge to get FDA approval and use their own sales force to create value, Celgene focuses heavily on internal R&D or acquires companies early in their development stage.

The company´s shares have sold off quite aggressively in response to a setback in what remains a very extensive and diversified pipeline, including many candidates which are in advanced stage of development. Pipeline success is needed in order to drive growth further and diversify the business away from Revlimid and other multiple myeloma drugs. Continued growth in earnings, and rapid margin expansion (as elevated R&D efforts are coming down), combined with the latest setback in the shares, makes that earnings multiples are reasonable at 20 times.

READ FULL ARTICLE HERE